BMRN
Biomarin Pharmaceutical Inc
NASDAQ: BMRN · HEALTHCARE · BIOTECHNOLOGY
$54.21
+1.71% today
Updated 2026-04-29
Market cap
$10.48B
P/E ratio
30.12
P/S ratio
3.25x
EPS (TTM)
$1.80
Dividend yield
—
52W range
$51 – $66
Volume
2.0M
WallStSmart proprietary scores
75
out of 100
Grade: B+
Buy
Investment rating
8.7
Growth
A4.8
Quality
C6.0
Profitability
B7.3
Valuation
B+2/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$90.17
+66.33%
12-Month target
$54.67
+0.85%
Intrinsic (DCF)
$188.60
Margin of safety
+68.02%
4 Strong Buy14 Buy5 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $58.92M — positive
+ Revenue growth 17.00% QoQ
+ 68.02% below intrinsic value
Risks
- Piotroski 2/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.10B | $2.42B | $2.85B | $3.22B | $3.22B |
| Net income | $141.56M | $167.65M | $426.86M | $348.90M | $-46.57M |
| EPS | — | — | — | — | $1.80 |
| Free cash flow | $54.94M | $62.57M | $475.42M | $724.96M | $58.92M |
| Profit margin | 6.75% | 6.93% | 14.96% | 10.83% | 10.80% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-18 | DAVIS, GEORGE ERIC | Sale | 1,273 | $56.05 |
| 2026-03-17 | MUELLER, BRIAN | Sale | 2,117 | $56.05 |
| 2026-03-17 | HUBBARD, CRISTIN | Sale | 1,245 | $56.05 |
Peer comparison
Smart narrative
Biomarin Pharmaceutical Inc trades at $54.21. representing a P/E of 30.12x trailing earnings. Our Smart Value Score of 75/100 indicates the stock is good. The company scores 2/9 on the Piotroski F-Score. TTM revenue stands at $3.22B. with profit margins at 10.80%. Our DCF model estimates intrinsic value at $188.60.
Frequently asked questions
What is Biomarin Pharmaceutical Inc's stock price?
Biomarin Pharmaceutical Inc (BMRN) trades at $54.21.
Is Biomarin Pharmaceutical Inc overvalued?
Smart Value Score 75/100 (Grade B+, Buy). DCF value $188.60.
What is the price target of Biomarin Pharmaceutical Inc (BMRN)?
The analyst target price is $90.17, representing +66.3% upside from the current price of $54.21.
What is the intrinsic value of Biomarin Pharmaceutical Inc (BMRN)?
Based on our DCF model, intrinsic value is $188.60, a +68.0% margin of safety versus $54.21.
What is Biomarin Pharmaceutical Inc's revenue?
TTM revenue is $3.22B.
Piotroski F-Score?
2/9 — weak financial health.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio3.25x
ROE5.94%
Beta0.29
50D MA$57.25
200D MA$56.40
Shares out0.19B
Float0.19B
Short ratio—
Avg volume2.0M
Performance
1 week-3.01%
1 month-6.80%
3 months-1.21%
YTD-8.24%
1 year—
3 years—
5 years—